A phase 1 study of oral CC5013, an immunomodulatory thalidomide (Thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).
暂无分享，去创建一个
N. Munshi | P. Richardson | D. Chauhan | T. Hideshima | F. Davies | K. Kelly | J. Zeldis | R. Schlossman | Sheeba K. Thomas | R. LeBlanc | E. Weller | L. Catley | M. McKenney | D. Doss | J. Ryoo | A. Freeman | K. Anderson | Rebecca Rich | Julie Mechlowicz | Reggie Deocampo | M. Mckenney | S. Thomas